Pair Name | Beta-Elemene, Bevacizumab | ||
Phytochemical Name | Beta-Elemene (PubChem CID: 6918391 ) | ||
Anticancer drug Name | Bevacizumab (PubChem CID: / ) | ||
Structure of Phytochemical |
Download
2D
MOL
3D
MOL
|
||
Structure of Anticancer Drug |
Download
2D
MOL
3D
MOL
|
Pair Name | Beta-Elemene, Bevacizumab | |||
Disease Info | [ICD-11: 2B90] | Colon cancer | Investigative | |
Biological Phenomena | Induction-->Apoptosis | |||
Gene Regulation | Down-regulation | Expression | BCL2 | hsa596 |
Down-regulation | Expression | MKI67 | hsa4288 | |
Down-regulation | Expression | PECAM1 | hsa5175 | |
Down-regulation | Expression | VEGFA | hsa7422 | |
In Vitro Model | HCT 116 | Colon carcinoma | Homo sapiens (Human) | CVCL_0291 |
In Vivo Model | HCT-116 cells in the logarithmic growth phase were selected and suspended in PBS after 0.25% pancreatic enzyme digestion (cell concentration: 1×10⁷/mL, living cells >95% after trypan blue staining). Nude mice were intraperitoneally injected with 0.2 mL of the cell suspension (total, 2×106 cells/mice) in the right axilla. | |||
Result | Bevacizumab exerts a synergistic effect with β-elemene in suppressing the growth of tumors derived from HCT-116 cells, and the related mechanisms may include the inhibition of tumor cell proliferation and tumor angiogenesis and the promotion of tumor cell apoptosis. |
No. | Title | Href |
---|---|---|
1 | Synergistic effects of bevacizumab in combination with β-elemene on subcutaneous xenografts derived from HCT-116 human colon cancer cells. Transl Cancer Res. 2020 Feb;9(2):1001-1011. doi: 10.21037/tcr.2019.12.35. | Click |